Cala Health Inc (Cala Health) is a bioelectronic company that strives to develop new class of electrical medicines. The company’s neuroperipheral therapy treats chronic disease by activating peripheral nerves with body-worn electronics. Its Cala ONE is a non-invasive, targeted nerve stimulator for the treatment of essential tremor. Cala Health aims to provide individualized, prescription neuromodulation therapies in combination with neuroscience and electronics. The company is funded by Lightstone Ventures, Lux Capital, dRx Capital, GV and Action Potential Venture Capital, among others. Cala Health is headquartered in San Mateo, California, the US.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Cala Health Inc
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design, trial status and phase, estimated start and end date.
Reasons to Buy:
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Table of Contents
- Cala Health Inc Company Overview
- Cala Health Inc Company Snapshot
- Cala Health Inc Pipeline Products and Ongoing Clinical Trials Overview
- Cala Health Inc - Pipeline Analysis Overview
- Cala Health Inc - Key Facts
- Cala Health Inc - Major Products and Services
- Cala Health Inc Pipeline Products by Development Stage
- Cala Health Inc Ongoing Clinical Trials by Trial Status
- Cala Health Inc Pipeline Products Overview
- Cala Trio - Action Tremor
- Cala Trio - Action Tremor Product Overview
- RAVANS Device
- RAVANS Device Product Overview
- RAVANS Device Clinical Trial
- Wearable Neuromodulation Device
- Wearable Neuromodulation Device Product Overview
- Wearable Neuromodulation Device - Cardiology
- Wearable Neuromodulation Device - Cardiology Product Overview
- Wearable Neuromodulation Device - Cardiology Clinical Trial
- Wearable Neuromodulation Device - Motor Function
- Wearable Neuromodulation Device - Motor Function Product Overview
- Wearable Neuromodulation Device - Psychiatry
- Wearable Neuromodulation Device - Psychiatry Product Overview
- Cala Health Inc - Key Competitors
- Cala Health Inc - Key Employees
- Cala Health Inc - Locations And Subsidiaries
- Head Office
- Recent Developments
- Cala Health Inc, Recent Developments
- Jan 09, 2024: Cala Announces Data from Multiple Clinical Studies Demonstrating Effective Outcomes of Transcutaneous Afferent Patterned Stimulation (TAPS) Therapy in Essential Tremor (ET) Patients
- Oct 25, 2023: Cala kIQ System to Treat Hand Tremor Named to Time’s List of the Best Inventions of 2023
- Jun 14, 2023: Cala Launches The Cala kIQ System, Offering Meaningful Tremor Relief for Patients With Essential Tremor and Now Parkinson’s Disease
- Apr 19, 2023: Cala introduces next generation system and accelerates leadership in bioelectronic medicine
- Dec 02, 2022: Cala Health receives additional 510(k) clearance for Cala kIQ
- Sep 27, 2022: Real world evidence of Cala TAPS therapy further supports long-term safety and efficacy of its treatment for essential tremor
- May 18, 2022: Cala Partners with SK Biopharmaceuticals to Fuel Innovation in Neurology
- Apr 04, 2022: New research presented at AAN demonstrates burden associated with essential tremor and the unmet patient need
- Mar 01, 2022: Cala Health is building momentum by expanding affordable access for patients with essential tremor
- Oct 12, 2021: Cala Health receives additional 510(k) clearance for Cala Trio
- Appendix
- Methodology
- About the Publisher
- Contact the Publisher
- Disclaimer
- Cala Health Inc Pipeline Products and Ongoing Clinical Trials Overview
- Cala Health Inc Pipeline Products by Equipment Type
- Cala Health Inc Pipeline Products by Indication
- Cala Health Inc Ongoing Clinical Trials by Trial Status
- Cala Health Inc, Key Facts
- Cala Health Inc, Major Products and Services
- Cala Health Inc Number of Pipeline Products by Development Stage
- Cala Health Inc Pipeline Products Summary by Development Stage
- Cala Health Inc Ongoing Clinical Trials by Trial Status
- Cala Health Inc Ongoing Clinical Trials Summary
- Cala Trio - Action Tremor - Product Status
- Cala Trio - Action Tremor - Product Description
- RAVANS Device - Product Status
- RAVANS Device - Product Description
- RAVANS Device - Investigating the Safety and Efficacy of Respiratory-Gated Auricular Vagal Afferent Nerve Stimulation (RAVANS) in Ulcerative Colitis (UC) in Pediatric and Young Adult Populations
- Wearable Neuromodulation Device - Product Status
- Wearable Neuromodulation Device - Product Description
- Wearable Neuromodulation Device - Cardiology - Product Status
- Wearable Neuromodulation Device - Cardiology - Product Description
- Wearable Neuromodulation Device - Cardiology - A Feasibility Study of Peripheral Nerve Stimulation Therapy for Atrial Fibrillation
- Wearable Neuromodulation Device - Motor Function - Product Status
- Wearable Neuromodulation Device - Motor Function - Product Description
- Wearable Neuromodulation Device - Psychiatry - Product Status
- Wearable Neuromodulation Device - Psychiatry - Product Description
- Cala Health Inc, Key Employees
- Glossary
- Cala Health Inc Pipeline Products by Equipment Type
- Cala Health Inc Pipeline Products by Development Stage
- Cala Health Inc Ongoing Clinical Trials by Trial Status
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Soterix Medical Inc
- NeuroMetrix Inc
- LivaNova USA Inc
- NeuroPace Inc
- NeuSpera Medical Inc
- Soterix Medical Inc
- NeuSpera Medical Inc
- Cyberonics Inc
